Recent Advances in the Noninvasive Prenatal Testing for Chromosomal Abnormalities Using Maternal Plasma DNA
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要No single invention in the past has created such a rapid and massive impact on clinical obstetric practice as the introduction of noninvasive prenatal screening (NIPS) for chromosomal abnormalities using cell-free DNA in maternal plasma. However, the technology of NIPS which has also been called noninvasive prenatal testing (NIPT) is rapidly evolving. Most clinicians may not be able to fully understand this new technology to enable good clinical practice. This review will be focused on issues that have important clinical implications. NIPT/S is only a screening test and all positive cases must be confirmed by invasive diagnostic techniques. Although NIPT/S is being expanded rapidly to cover other chromosomes and large chromosomal structural abnormalities, the detection rate is still uncertain, and the positive predictive value is expected to be lower. Pregnant women who are at risk of chromosomal abnormalities other than common trisomies should be offered a diagnostic test instead of NIPT/S. The use of NIPT/S as a primary Down syndrome screening test should not replace the 11-13 weeks scan.
著者Lau TK, Zhu XF, Kwok YKY, Leung TY, Choy KW
期刊名稱Journal of Fetal Medicine
出版年份2020
月份3
卷號7
期次1
出版社Springer
頁次17 - 23
國際標準期刊號2348-1153
電子國際標準期刊號2348-8859
語言英式英語
關鍵詞Noninvasive prenatal screening, NIPS, NIPT, Cell-free DNA, Maternal plasma, Aneuploidy
Web of Science 學科類別Obstetrics & Gynecology;Obstetrics & Gynecology

上次更新時間 2020-21-09 於 00:29